EP
NVO

Eudaimonia Partners’s Novo Nordisk NVO Stock Holding History

Eudaimonia Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-930
Closed -$31K – 1020
2021
Q1 		$31K Buy
930
+350
+60% +$12.5K 0.01% 797
2020
Q4 		$20K Sell
580
-176
-23% -$6.08K ﹤0.01% 871
2020
Q3 		$26K Sell
756
-420
-36% -$14K 0.01% 732
2020
Q2 		$39K Sell
1,176
-1,094
-48% -$34.9K 0.01% 557
2020
Q1 		$68K Buy
2,270
+1,270
+127% +$37.8K 0.03% 408
2019
Q4 		$29K Buy
+1,000
New +$27.7K 0.01% 613

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Eudaimonia Partners's NVO Position: Q2 2021 in Review

Eudaimonia Partners sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 930 shares — an estimated $31K sold.

Eudaimonia Partners first reported a position in NVO in Q4 2019 and held it in 6 quarters. The position peaked at $68K in Q1 2020. 735 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

  • Eudaimonia Partners reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 930 Novo Nordisk shares in Q2 2021, an estimated $31K.
  • Eudaimonia Partners first reported a position in Novo Nordisk in Q4 2019 and held it in 6 quarters.
  • Eudaimonia Partners's Novo Nordisk position peaked at $68K in Q1 2020.
  • 735 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.